Med-tech deal values climbed to $424.5 million in November, after October ranked as the lowest monthly total of the year with $15.9 million in deal value.

By the end of November 2024, the BioWorld Neurological Diseases Index had dropped 13.4%, deepening its decline of 9.4% at the end of August. Meanwhile, the Dow Jones Industrial Average surged 19.16% in the first 11 months of the year, building on a 10.81% gain reported at the end of October. The Nasdaq Biotechnology Index posted a year-to-date increase of 6.27% through November, retreating from its peak gain of 11.7% in August.

Biopharma companies have raised $97.42 billion through November 2024, up 46% from $66.79 billion during the same period in 2023 and also more than $56.56 billion in 2022.

Beijing Hanmi Pharm. Co. Ltd. broke ground on a ₩140 billion (US$98.65 million) large-scale project to build a near-500,000-square-foot China base near Beijing Capital International Airport in efforts to increase the company’s local production, R&D and office capabilities.

Med-tech firms raised $23.65 billion in financings through November, an increase of 42% from $16.61 billion raised in the first 11 months of 2023. November’s value totaled $919.99 million, down from October’s $1.43 billion and $1.02 billion in September, but up from August's $3.67 billion.